GW501516-activated PPARβ/δ promotes liver fibrosis via p38-JNK MAPK-induced hepatic stellate cell proliferation

Cell and Bioscience

Volumn 2, Issue 1, 2012, Pages

  Kostadinova, Radina ^a,b   Montagner, Alexandra ^a,c   Gouranton, Erwan ^a   Fleury, Sébastien ^d   Guillou, Hervé ^c   Dombrowicz, David ^d   Desreumaux, Pierre ^d   Wahli, Walter ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c TOXALIM RESEARCH CENTRE IN FOOD TOXICOLOGY   (France)

^d UNIV LILLE   (France)

Author keywords

Fibrosis; Inflammation; Peroxisome proliferator activated receptor ; Proliferation; Signaling pathways

Indexed keywords

MUS;

EID: 84870946722     PISSN: None     EISSN: 20453701     Source Type: Journal    
DOI: 10.1186/2045-3701-2-34     Document Type: Article

References (43)

1. Elsharkawy AM, Oakley F, Mann DA. The role and regulation of hepatic stellate cell apoptosis in reversal of liver fibrosis. Apoptosis 2005, 10:927-939. 10.1007/s10495-005-1055-4, 16151628.
2. Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 2000, 275:2247-2250. 10.1074/jbc.275.4.2247, 10644669.
3. Gressner AM. The cell biology of liver fibrogenesis - an imbalance of proliferation, growth arrest and apoptosis of myofibroblasts. Cell Tissue Res 1998, 292:447-452. 10.1007/s004410051073, 9582401.
4. Michalik L, Wahli W. Involvement of PPAR nuclear receptors in tissue injury and wound repair. The Journal of clinical investigation 2006, 116:598-606. 10.1172/JCI27958, 1386118, 16511592.
5. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999, 20:649-688. 10.1210/er.20.5.649, 10529898.
6. Manautou JE, Silva VM, Hennig GE, Whiteley HE. Repeated dosing with the peroxisome proliferator clofibrate decreases the toxicity of model hepatotoxic agents in male mice. Toxicology 1998, 127:1-10. 10.1016/S0300-483X(98)00013-4, 9699788.
7. Galli A, Crabb DW, Ceni E, Salzano R, Mello T, Svegliati-Baroni G, Ridolfi F, Trozzi L, Surrenti C, Casini A. Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology 2002, 122:1924-1940. 10.1053/gast.2002.33666, 12055599.
8. Yuan GJ, Zhang ML, Gong ZJ. Effects of PPARg agonist pioglitazone on rat hepatic fibrosis. World J Gastroenterol 2004, 10:1047-1051.
9. Knight B, Yeap BB, Yeoh GC, Olynyk JK. Inhibition of adult liver progenitor (oval) cell growth and viability by an agonist of the peroxisome proliferator activated receptor (PPAR) family member gamma, but not alpha or delta. Carcinogenesis 2005, 26:1782-1792. 10.1093/carcin/bgi138, 15917308.
10. Hellemans K, Michalik L, Dittie A, Knorr A, Rombouts K, De Jong J, Heirman C, Quartier E, Schuit F, Wahli W, Geerts A. Peroxisome proliferator-activated receptor-beta signaling contributes to enhanced proliferation of hepatic stellate cells. Gastroenterology 2003, 124:184-201. 10.1053/gast.2003.50015, 12512042.
11. Hellemans K, Rombouts K, Quartier E, Dittie AS, Knorr A, Michalik L, Rogiers V, Schuit F, Wahli W, Geerts A. PPARbeta regulates vitamin A metabolism-related gene expression in hepatic stellate cells undergoing activation. J Lipid Res 2003, 44:280-295. 10.1194/jlr.M200376-JLR200, 12576510.
12. Shan W, Nicol CJ, Ito S, Bility MT, Kennett MJ, Ward JM, Gonzalez FJ, Peters JM. Peroxisome proliferator-activated receptor-beta/delta protects against chemically induced liver toxicity in mice. Hepatology 2008, 47:225-235.
13. Shan W, Palkar PS, Murray IA, McDevitt EI, Kennett MJ, Kang BH, Isom HC, Perdew GH, Gonzalez FJ, Peters JM. Ligand activation of peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) attenuates carbon tetrachloride hepatotoxicity by downregulating proinflammatory gene expression. Toxicol Sci 2008, 105:418-428. Epub 2008 Jul 2012, 10.1093/toxsci/kfn142, 2527639, 18622026.
14. Pang M, de la Monte SM, Longato L, Tong M, He J, Chaudhry R, Duan K, Ouh J, Wands JR. PPARdelta agonist attenuates alcohol-induced hepatic insulin resistance and improves liver injury and repair. J Hepatol 2009, 50:1192-1201. Epub 2009 Mar 1120, 10.1016/j.jhep.2009.01.021, 2680444, 19398227.
15. Iwaisako K, Haimerl M, Paik YH, Taura K, Kodama Y, Sirlin C, Yu E, Yu RT, Downes M, Evans RM, Brenner DA, Schnabl B. Protection from liver fibrosis by a peroxisome proliferator-activated receptor delta agonist. Proceedings of the National Academy of Sciences of the United States of America 2012,
16. Weber LW, Boll M, Stampfl A. Hepatotoxicity and mechanism of action of haloalkanes: carbon tetrachloride as a toxicological model. Critical reviews in toxicology 2003, 33:105-136. 10.1080/713611034, 12708612.
17. Xu L, Hui AY, Albanis E, Arthur MJ, O'Byrne SM, Blaner WS, Mukherjee P, Friedman SL, Eng FJ. Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis. Gut 2005, 54:142-151. 10.1136/gut.2004.042127, 1774377, 15591520.
18. Taimr P, Higuchi H, Kocova E, Rippe RA, Friedman S, Gores GJ. Activated stellate cells express the TRAIL receptor-2/death receptor-5 and undergo TRAIL-mediated apoptosis. Hepatology 2003, 37:87-95. 10.1053/jhep.2003.50002, 12500193.
19. Gallo KA, Johnson GL. Mixed-lineage kinase control of JNK and p38 MAPK pathways. Nat Rev Mol Cell Biol 2002, 3:663-672. 10.1038/nrm906, 12209126.
20. Kim KY, Kim BC, Xu Z, Kim SJ. Mixed lineage kinase 3 (MLK3)-activated p38 MAP kinase mediates transforming growth factor-beta-induced apoptosis in hepatoma cells. J Biol Chem 2004, 279:29478-29484. Epub 22004 Apr 29476, 10.1074/jbc.M313947200, 15069087.
21. Chadee DN, Kyriakis JM. MLK3 is required for mitogen activation of B-Raf, ERK and cell proliferation. Nat Cell Biol 2004, 6:770-776. Epub 2004 Jul 2018, 10.1038/ncb1152, 15258589.
22. Chadee DN, Kyriakis JM. A novel role for mixed lineage kinase 3 (MLK3) in B-Raf activation and cell proliferation. Cell Cycle 2004, 3:1227-1229. Epub 2004 Oct 1219, 10.4161/cc.3.10.1187, 15467451.
23. Michalik L, Desvergne B, Tan NS, Basu-Modak S, Escher P, Rieusset J, Peters JM, Kaya G, Gonzalez FJ, Zakany J, Metzger D, Chambon P, Duboule D, Wahli W. Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR)alpha and PPARbeta mutant mice. The Journal of cell biology 2001, 154:799-814. 10.1083/jcb.200011148, 2196455, 11514592.
24. Schnabl B, Bradham CA, Bennett BL, Manning AM, Stefanovic B, Brenner DA. TAK1/JNK and p38 have opposite effects on rat hepatic stellate cells. Hepatology 2001, 34:953-963. 10.1053/jhep.2001.28790, 11679966.
25. Parsons CJ, Takashima M, Rippe RA. Molecular mechanisms of hepatic fibrogenesis. J Gastroenterol Hepatol 2007, 22:S79-84. 10.1111/j.1440-1746.2006.04659.x, 17567474.
26. Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002, 298:1911-1912. 10.1126/science.1072682, 12471242.
27. Di-Poi N, Tan NS, Michalik L, Wahli W, Desvergne B. Antiapoptotic role of PPARbeta in keratinocytes via transcriptional control of the Akt1 signaling pathway. Mol Cell 2002, 10:721-733. 10.1016/S1097-2765(02)00646-9, 12419217.
28. Ramm GA, Li L, Britton RS, O'Neill R, Bacon BR. Effect of protein kinase C activation and inhibition on rat hepatic stellate cell activation. Dig Dis Sci 2003, 48:790-796. 10.1023/A:1022857313917, 12741473.
29. Di Sario A, Bendia E, Svegliati-Baroni G, Marzioni M, Ridolfi F, Trozzi L, Ugili L, Saccomanno S, Jezequel AM, Benedetti A. Rearrangement of the cytoskeletal network induced by platelet-derived growth factor in rat hepatic stellate cells: role of different intracellular signalling pathways. J Hepatol 2002, 36:179-190.
30. Takahashi M, Matsui A, Inao M, Mochida S, Fujiwara K. ERK/MAPK-dependent PI3K/Akt phosphorylation through VEGFR-1 after VEGF stimulation in activated hepatic stellate cells. Hepatol Res 2003, 26:232-236. 10.1016/S1386-6346(03)00112-8, 12850696.
31. Sugimoto R, Enjoji M, Kohjima M, Tsuruta S, Fukushima M, Iwao M, Sonta T, Kotoh K, Inoguchi T, Nakamuta M. High glucose stimulates hepatic stellate cells to proliferate and to produce collagen through free radical production and activation of mitogen-activated protein kinase. Liver Int 2005, 25:1018-1026. 10.1111/j.1478-3231.2005.01130.x, 16162162.
32. Casini A, Galli G, Salzano R, Ceni E, Franceschelli F, Rotella CM, Surrenti C. Acetaldehyde induces c-fos and c-jun proto-oncogenes in fat-storing cell cultures through protein kinase C activation. Alcohol Alcohol 1994, 29:303-314.
33. Anania FA, Womack L, Potter JJ, Mezey E. Acetaldehyde enhances murine alpha2(I) collagen promoter activity by Ca2+-independent protein kinase C activation in cultured rat hepatic stellate cells. Alcohol Clin Exp Res 1999, 23:279-284.
34. Jaeschke A, Davis RJ. Metabolic stress signaling mediated by mixed-lineage kinases. Mol Cell 2007, 27:498-508. 10.1016/j.molcel.2007.07.008, 1986670, 17679097.
35. Tournier C, Dong C, Turner TK, Jones SN, Flavell RA, Davis RJ. MKK7 is an essential component of the JNK signal transduction pathway activated by proinflammatory cytokines. Genes Dev 2001, 15:1419-1426. 10.1101/gad.888501, 312702, 11390361.
36. Chadee DN, Xu D, Hung G, Andalibi A, Lim DJ, Luo Z, Gutmann DH, Kyriakis JM. Mixed-lineage kinase 3 regulates B-Raf through maintenance of the B-Raf/Raf-1 complex and inhibition by the NF2 tumor suppressor protein. Proc Natl Acad Sci U S A 2006, 103:4463-4468. Epub 2006 Mar 4413, 10.1073/pnas.0510651103, 1450194, 16537381.
37. Hashimoto S, Gon Y, Takeshita I, Matsumoto K, Maruoka S, Horie T. Transforming growth Factor-beta1 induces phenotypic modulation of human lung fibroblasts to myofibroblast through a c-Jun-NH2-terminal kinase-dependent pathway. Am J Respir Crit Care Med 2001, 163:152-157.
38. Wagner AC, Mazzucchelli L, Miller M, Camoratto AM, Goke B. CEP-1347 inhibits caerulein-induced rat pancreatic JNK activation and ameliorates caerulein pancreatitis. Am J Physiol Gastrointest Liver Physiol 2000, 278:G165-172.
39. Saporito MS, Hudkins RL, Maroney AC. Discovery of CEP-1347/KT-7515, an inhibitor of the JNK/SAPK pathway for the treatment of neurodegenerative diseases. Prog Med Chem 2002, 40:23-62.
40. Zadravec D, Brolinson A, Fisher RM, Carneheim C, Csikasz RI, Bertrand-Michel J, Boren J, Guillou H, Rudling M, Jacobsson A. Ablation of the very-long-chain fatty acid elongase ELOVL3 in mice leads to constrained lipid storage and resistance to diet-induced obesity. The FASEB journal: official publication of the Federation of American Societies for Experimental Biology 2010, 24:4366-4377.
41. Hautekeete ML, Dodeman I, Azais-Braesco V, Van den Berg K, Seynaeve C, Geerts A. Hepatic stellate cells and liver retinoid content in alcoholic liver disease in humans. Alcohol Clin Exp Res 1998, 22:494-500. 10.1111/j.1530-0277.1998.tb03678.x, 9581658.
42. Nadra K, Anghel SI, Joye E, Tan NS, Basu-Modak S, Trono D, Wahli W, Desvergne B. Differentiation of trophoblast giant cells and their metabolic functions are dependent on peroxisome proliferator-activated receptor beta/delta. Mol Cell Biol 2006, 26:3266-3281. 10.1128/MCB.26.8.3266-3281.2006, 1446964, 16581799.
43. Wiznerowicz M, Trono D. Conditional suppression of cellular genes: lentivirus vector-mediated drug-inducible RNA interference. J Virol 2003, 77:8957-8961. 10.1128/JVI.77.16.8957-8951.2003, 167245, 12885912.